Plus, Trulicity blocks glucagon
Read her highlights and what they mean for your business: #TOPRASymposium #RegulatoryAffairs #Pharma #EURegulations #MHRA #Compliance #PartnerOfChoice To view or add a comment, sign in One month on, Nicola Gover shares her lasting insights from this years TOPRA - The Organisation for Professionals in Regulatory Affairs Symposium in Berlin
Saxagliptin has significant drug interactions because it is extensively metabolized by CYP 3A4/5 and to a lesser extent CYP 2C8 in the liver (Dave, 2011)
This is when a dose reduction or dose splitting conversation becomes appropriate
The supplement industry regulatory framework, designed in 1994, was not built for the era of social media marketing and anonymous e-commerce
The Health and Healthcare Spending Effects of GLP-1s Glucagon-like peptide-1 receptor agonists (GLP-1s), better known by brand names such as Ozempic and Wegovy, have generated intense interest as potentially transformative treatments for type 2 diabetes and obesity